Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function

被引:13
作者
Sælen, MG
Prosch, LK
Gudmundsdottir, H
Dyrbekk, D
Hunderi, OH
Arnesen, E
Paulsen, D
Skjonsberg, H
Os, I [1 ]
机构
[1] Ullevaal Univ Hosp, Dept Nephrol, N-0407 Oslo, Norway
[2] Univ Oslo, Dept Pharmacotherapeut, Oslo, Norway
[3] Vestfold HF, Tensberg, Norway
[4] Ostfold HF, Fredrikstad, Norway
[5] Innlandet HF Elverum, Elverum, Norway
[6] Innlandet HF Lillehammer, Lillehammer, Norway
[7] Akershus Univ Hosp, Nordbyhagen, Norway
关键词
antihypertensive drugs; blood pressure control; chronic renal failure; diabetic kidney disease;
D O I
10.1080/08037050510008959
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
This study compared the use of antihypertensive treatment and blood pressure ( BP) controls between patients with diabetic kidney disease (DK+) and patients with non-diabetic kidney disease (DK-) exhibiting moderate-to-severe chronic renal failure who did not need renal replacement therapy. A cross-sectional survey included all renal patients with s-creatinine at >= 200 mu mol/l attending regular control sessions at six renal units in Norway. Of the 351 patients included, 73 (20.8%) were DK+. The proportion reaching a BP goal of <130/80 mmHg was similar in DK+ and DK- (14.1% vs 13.6%, p=0.92), while 38% and 39% achieved a BP of <140/90 mmHg, respectively. The systolic BP goal was more difficult to achieve than the diastolic BP goal in DK+ patients (35% vs 15%) despite a mean of three different types of drugs being used. Loop diuretics and beta-adrenergic-receptor antagonists were the most frequently prescribed drugs, and the use of angiotensin-converting enzyme inhibitors or angiotensin-II-receptor antagonists declined when renal function deteriorated, from 80% to 0% and from 66% to 20% in the DK+ and DK- groups, respectively (p=0.001). Thus, despite the use of multiple antihypertensive drugs, controlling BP-especially the systolic BP-is difficult in high-risk patients with chronic renal failure caused by diabetic kidney disease.
引用
收藏
页码:170 / 176
页数:7
相关论文
共 33 条
[21]   Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and Lisinopril microalbuminuria (CALM) study [J].
Mogensen, CE ;
Neldam, S ;
Tikkanen, I ;
Oren, S ;
Viskoper, R ;
Watts, RW ;
Cooper, ME .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7274) :1440-1444
[22]   RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial (Retracted article. See vol. 374, pg. 1226, 2009) [J].
Nakao, N ;
Yoshimura, A ;
Morita, H ;
Takada, M ;
Kayano, T ;
Ideura, T .
LANCET, 2003, 361 (9352) :117-124
[23]   Sympathetic overactivity and arterial hypertension in renal failure [J].
Orth, SR ;
Amann, K ;
Strojek, K ;
Ritz, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 :67-69
[24]  
Pisoni R, 2002, J NEPHROL, V15, P428
[25]  
PROSCH LK, 2005, IN PRESS SCAND J URO
[26]   Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus [J].
Rosner, MH ;
Okusa, MD .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (09) :1025-1029
[27]  
Ruggenenti P, 2001, J AM SOC NEPHROL, V12, P2832, DOI 10.1681/ASN.V12122832
[28]   Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes [J].
Schrier, RW ;
Estacio, RO ;
Esler, A ;
Mehler, P .
KIDNEY INTERNATIONAL, 2002, 61 (03) :1086-1097
[29]  
Tepel M, 2002, CLIN SCI, V103, P511, DOI 10.1042/CS20020094
[30]   Treating hypertension in diabetic nephropathy [J].
Tomlinson, JW ;
Owen, KR ;
Close, CF .
DIABETES CARE, 2003, 26 (06) :1802-1805